Question
Does the combination of baricitinib and remdesivir improve outcomes in patients hospitalized with COVID-19?
Conclusion
For hospitalized patients with COVID-19 and evidence of lower respiratory tract infection, the combination of baracitinib plus remdesivir results in faster time to recovery, especially in patients who require noninvasive mechanical ventilation or high-flow oxygen. No survival benefit is seen with this combination.
Recent Posts
- Are platelet-rich plasma injections, either single or multiple, more effective than saline injections in adults with early symptomatic degenerative joint disease of the knee?
- No advantage to 325 mg over 81 mg aspirin for persons with established cardiovascular disease (ADAPTABLE)
- How do ibuprofen, ketorolac, and diclofenac compare for the treatment of acute, nonradicular low back pain in adults?
- Are platelet-rich plasma injections effective for alleviating pain and improving function in adults with symptomatic ankle osteoarthritis?
- Recurrent herpes zoster more common in women, younger adults, and the immunosuppressed
Leave A Comment